Solid Biosciences Inc.
SLDBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SLDB Earnings Report
EPS Est: $-0.43 | FQ end 2026-06
How SLDB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SGT-003 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Solid Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Solid Biosciences Inc.'s (SLDB) pipeline across Phase 3. Its lead program is SGT-003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Solid Biosciences Inc.'s next FDA catalyst?→
Solid Biosciences Inc.'s (SLDB) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SLDB biotech catalysts?→
Add SLDB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Solid Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.